Riociguat is a first-in-class sGC stimulator approved in 2013 for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The gene discussed is SGCB; the disease is chronic thromboembolic pulmonary hypertension.